CA2222929A1 - Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork - Google Patents

Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork Download PDF

Info

Publication number
CA2222929A1
CA2222929A1 CA002222929A CA2222929A CA2222929A1 CA 2222929 A1 CA2222929 A1 CA 2222929A1 CA 002222929 A CA002222929 A CA 002222929A CA 2222929 A CA2222929 A CA 2222929A CA 2222929 A1 CA2222929 A1 CA 2222929A1
Authority
CA
Canada
Prior art keywords
composition
cells
diclofenac
trabecular
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222929A
Other languages
French (fr)
Inventor
Donald J. Fauss
Jon R. Polansky
Ernest Bloom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2222929A1 publication Critical patent/CA2222929A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury of the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells.
Such treatment can ameliorate the severity or prevent glaucoma.

Description

NON-STEROIDAL ANTI-INFJAMMATORY DRUGS FOR THE CYTO-PR~lt~llON OF THE
Ti~ABECU~AR MESHWORK

10 FIELD OF THE INYENTION:
The present invention is in the field of therapeutics, and concerns methods and reagents for protecting the cells of the trabecular meshwork from agents or processes that would otherwise result in trabecular cell loss. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.
BACKGROUND OF THE INVENTION:
aGlaucomas" are a group of debilitating eye diseases that are the leading cause of blindness subject to positive intervention 20 in the United States and other developed nations. The term "glaucoma" actually encompasses a variety of ophthalmic disease states which are caused by distinct disease processes or pathological conditions of the eye. The disease states under the term "glaucoma" generally share the characteristic of having 25 elevated intraocular pressure ("IOP"), which is a maior risk factor in producing visual field loss and blindness. Of the many different ophthalmic disease states, Chandler et al. (Glaucoma, 3d Ed., Lea and Febliger, Philadelphia (1986)) describe the following forms: primary open-angle glaucoma ("POAG"), progressive low-30 tension glaucoma, exfoliation and open-angle glaucoma ("OAG"), amylodosis and open-angle glaucoma, pigment dispersion and pigmentary glaucoma, angle-closure glaucoma, combined open-angle and angle-closure glaucoma, maiignant glaucoma, angle-closure glaucoma after scleral buckling operations for separated 3~ retina, angle-closure glaucoma due to a multiple cyst of iris and W O 96/40102 PCTrUS96/07340 ciliary body, angie-closure glaucoma secondary to occlusion of the central retinal vein, angle-closure glaucoma secondary to bilateral transitory myopia, glaucoma from perforating injuries, glaucoma from contusion of the eye, hemolytic or ghost-cell glaucoma, glaucoma associated with congenital and spontaneous dislocations of the lens, lens-induced glaucoma, glaucoma in aphasia, glaucoma due to intraocular inflammation, neovascular glaucoma, glaucoma associated with extra ocular venous congestion, essential atrophy of the iris with glaucoma.
corticosteroid glaucoma, glaucoma after penetrating keratoplasty and characteristically unilateral glaucomas. In almost all cases, the IOP found in these glaucoma syndromes results from an increase in aqueous outflow resistance (see, Vaughan, D. et at., In:
General Ophthamology, Appleton & Lange, Norwalk, CT, pp. 213-230 (1992)).
Primary open-angle glaucoma ("POAG"), also termed chronic open-angle glaucoma t"COAG"), is the most prevalent form of glaucoma. The incidence of this condition in persons over the age of forty is about 0.4 - 0.5%. (Leske, M.C. et al., Amer. J. Epidemiol.
113:1843-1846 (1986); Bengtsson, B., Br. J. Ophthamol. 73:483-~87 (1989); Strong, N.P., Ophthal. Physiol. Opt. 12:3-7 (1992)).
Moreover, the prevalence of the disease rises with age to over 6%
of those 75 years or older (Strong, N.P., Ophthal. Physiol. Opt.
12:3-7 (1992)). POAG is characterized by the loss of trabecular meshwork endothelial cells which is associated with degeneration of the normal structure of the trabecular meshwork. This degeneration leads to the obstruction of the normal ability of aqueous humor to leave the eye (see, Vaughan, D. et a/., In: General Ophthamology, Appleton & Lange, Norwalk, CT, pp. 213-230 (1992)).
In ordinary terminology, glaucoma is called "primary" if the pathogenic defect is believed to occur primarily within the tissue itself and without an obvious outside causal mechanism which can be defined for "secondary" glaucomas (e.g., see McGraw-Hill Encyclopedia of Science and Technology, 6th Ed., Vol. 8, p. 131 (McGraw-Hill 1987). In both POAG (for which no precise cause is w o 96140102 PCTrUS96/07340 known, although toxic substances produced locaily and/or from the aqueous humor are believed to account for trabecular cell damage/death) and pigmentary glaucoma (often classified as a secondary glaucoma since the pigment or other debris from the 5 posterior iris is thought to produce damage when engulfed by trabecular meshwork cells) there is known to be a marked loss of the endothelial cells of the meshwork. It is possible that oxidation products play a role in producing damage in the trabecular meshwork in both of these conditions, as well as in 10 ocular iron toxicity, which can also produce a glaucoma. It would be very important to protect trabecular meshwork endothelial cells from injury and death which occurs in the disease processes.
A loss in the number of trabecular meshwork cells and alteration in the function of the remaining cells is believed to be responsible 15 for a decrease in the normal ability of aqueous humor to leave the eye, leading to decreased outflow facility (increased outflow resistance), and elevated IOP.
It previously has been demonstrated that aging itself leads to a progressive loss of human trabecular meshwork cells which 20 also eventually leads to a compromise of the meshwork structure over time. Indeed, increased outflow resistance appears to occur in the non-glaucomatous aging population, and a method to preserve the cells in an aging normal individual as well as those with a recognized chronic glaucoma syndrome would be highly 2~ desirable. For these reasons, it would be desirable to have a means of treating or preventing pathological changes such as trabecular meshwork endothelial cell loss which are associated with the development and progression of these glaucoma syndromes. The present invention provides such improved 30 therapeutic agents and methods.
Elevated IOP results in progressive visual loss and blindness if not treated appropriately and in a timely fashion. The normal IOP for humans usually measures 10-20 mm Hg (1.3-2.7 kilopascals) and is maintained by a balance between the aqueous 3~ inflow and outflow; with rare exceptions, all glaucoma syndromes being associated with an outflow defect. The aqueous humor is W O 96/40102 PCT/U',G~'C7~40 produced by the ciliary body in the eye and passes from the posterior chamber through the papillary space into the anterior chamber. The aqueous drains through the trabecular meshwork into Schlemm's canal, through which it leaves the eye. Elevated 5 IOP is considered a major risk factor in producing damage to the optic nerve head, leading to loss of visual fields and eventually to blindness in many patients. Even in so called "normal tension glaucoma," lowering of an apparently normal IOP is thought to help prevent visual loss.
In the currently available treatments for glaucoma, one attempts to symptomatically lower the IOP by decreasing the amount of inflow (decreasing the rate of aqueous formation) or by increasing the facility of outflow. Although outflow can be increased by a variety of drugs, as will be appreciated, the available treatments do not address the underlying pathogenic processes in POAG, pigmentary glaucoma and other syndromes associated with cell loss (nor do they address the trabecular meshwork cell loss associated with normal aging).
Examples of various drug treatments that symptomatically reduce IOP (see, e.g., Babcock, J.C. et al., U.S. Patent 5,124,154;
Epstein, D.L., U.S. Patent 4,757,089; Doulakas, J., U.S. Patent No.
4,829,088) include: pilocarpine and epheneprine, which owe their effectiveness to increasing the facility of outflow; as well as timolol and other beta blockers, carbonic-anhydrase-inhibiting drugs, and alpha adrenergic agents, which owe their effectiveness to decreasing the rate of formation of aqueous.
Doulakas (U.S. Patent No. 4,829,088) discloses the use of an ophthalmic medicament containing diclofenac-sodium in aqueous solution for the treatment of inflammations of the eye.
Diclofenac-sodium is a non-steroidal anti-inflammatory ("NSAI") agent which is believed to be an alternative to corticosteroids (glucocorticoids) for the treatment of some inflammatory symptoms in the eye, and appears especially useful for the symptomatic relief of pain. The aqueous solution is made suitable for the local treatment of inflammations of the eye due to its .

W O 961401Q2 PCT/U'3~.~7~40 stability against chemical decomposition of the diclofenac-sodium and preservation properties and toleration by the eye.
Nagy (U.S. Patent No. 4,960,799) discloses aqueous ophthalmic solutions containing diclofenac-sodium. The solutions, having a pH of about 7.8, comprise per milliliter of solution about 0.1 to about 5.0 milligrams of (a) pharmaceutically acceptable salt of ortho-(2,6-dichlophenyl-)aminophenyl acetic acid; tb) about 0.1 to about 10 milligrams of a pharmaceutically acceptable sale of ethylene diamine tetraccetic acid, (c) about 0.5 to about 200 milligrams of a pharmaceutically acceptable solubilizer, (d) about 0.01 to about 5.0 milligrams of a pharmaceutically acceptable bacteriostat and (e) the remainder water. The ophthalmic solutions are used for topical administration to the eye for the control or treatment of ocular 1 5 inflammation.
Cherng-Chyi et al. (U.S. Patent No. 5,110,493) relates to ophthalmic non-steroidal anti-inflammatory drug formulations containing a quaternary ammonium preservative and a non-ionic surfactant. The formulations are useful for treating diseases that are either caused by, associated with or accompanied by inflammatory processes.
The above, and others in the well-known class of NSAI
agents have been proposed to suppress signs of inflammatory responses, to prevent particular side-effects of surgical trauma, especially fluid accumulating in the back of the eye, and the appearance of inflammatory cells and vessel leakage in the anterior chamber. NSAI agents useful in treating inflammation are known to inhibit prostaglandin production and also to affect other eicosanoid pathways. NSAI agents are believed to be a possible alternative for glucocorticoids to reduce inflammation and avoid side-effects due to these drugs (e.g., concealing the risk of deterioration as a result of bacterial or viral infection), but in practice, NSAI agents have proven to be much less effective in treating many different types of ocular inflammation.
There is no NSAI agent that has been proposed to overcome the loss of trabecular cells associated with normal aging, nor in W O 96/40102 PCTrU~,5~7~40 conditions in which cell loss and cell damage appear greater -- as in POAG, pigmentary glaucoma and some other glaucoma syndromes. Preventing or treating loss of trabecular cells is particularly important since the IOP control in many glaucomatous 5 patients eventually becomes a problem, which, even with optimal medical and surgical therapy, may lead to progressive visual loss.
It also has been demonstrated that aging itself leads to a progressive loss of human trabecular meshwork cells which will eventually lead to a compromise of the meshwork over time.
10 Indeed, increased outflow resistance appears to occur in the non-glaucomatous aging population, and a method to preserve the cells in an aging normal individual as well as those with a recognized chronic glaucoma syndrome would be highly desirable. For these reasons, it would be desirable to have a means of treating or 15 preventing pathological changes such as trabecular meshwork endothelial cell loss which are associated with the development and progression of these glaucoma syndromes. The present invention provides such improved therapeutic agents and methods.
SUMMARY OF THE INVENTION:
The invention concerns the recognition that a loss of trabecular cells and loss of the normal structure of the trabecular meshwork contribute to the increased intraocular pressure that characterizes glaucomas.
The invention further concerns the recognition that certain non-steroidal anti-inflammatory agents (in addition to known anti-oxidants, such as vitamin E) produce cytoprotective effects on trabecular cells. Such agents can thus be used, singularly, in combination with other NSAI agents, or in combination with other agents, to prevent or treat the loss of trabecular cells observed in glaucomatous patients.
In detail, the invention provides a method for cyto-protection of the trabecular meshwork, comprising administering to a human a composition including (a) an ophthalmologically effective amount of a non-steroidal cyclooxygenase inhibitor, and w ~ 96140102 PCTrUS96/07340 (b) a pharmaceutically acceptable carrier, to prevent the loss of trabecular cells.
The invention particularly concerns the embodiment wherein the NSAI agent is selected from the group of known 5 cyclooxygenase inhibitor consisting of salicylates, indoles, phenylalkanoic acids, phenylacetic acids and pyrazolons, or from the group consisting of diclofenac, indomethacin and fenoprofen.
The invention additionally concerns the embodiment wherein the composition is administered topically (as in an aqueous 10 polymeric solution, aqueous suspension, ointment or gel vehicle), or by intraocular injection, oral administration (as with an aqueous solution, aqueous suspension, elixir, tablet, caplet or capsule) and intravenous injection.
The invention additionally provides a method for cyt o -15 protection of the trabecular meshwork, comprising administeringto a human a composition including (a) an ophthamologically effective amount of diclofenac, and (b) a pharmaceutically acceptable carrier, including a lightly cross-linked carboxy-containing polymer, in the form of an aqueous polymeric solution, 20 suspension, ointment or gel for topical administration, to prevent the loss of trabecular cells.
The invention additionally provides a method for cyto-protection of the trabecular meshwork, comprising administering to a human in need of treatment or prevention of oxidative injury 25 to its trabecular cells, or of damage to the trabecular cells from phagocytic or endocytic processes or other causes, a composition including (a) an ophthalmically effective amount of a non-steroidal anti-inflammatory cyclooxygenase inhibitor and (b) a pharmaceutically inert carrier, to prevent the loss of trabecular 30 cells.
The invention also provides a composition for cyto-protection of the trabecular meshwork, comprising (a) a non-steroidal cyclooxygenase inhibitor of a type and in an amount to prevent trabecular cell, and (b) a pharmaceutically acceptable 35 carrier therefor. In particular, the composition contains diclofenac, indomethecin or fenoprofen.

CA 02222929 l997-l2-Ol W O 96/40102 PCTrUS96/07340 DETAILED DESCRIPTION OF THE INVENTION:
I . Overview of the Invention Human trabecular meshwork (HTM) cells are endothelial-like cells that line the outflow channels by which aqueous humor exits 5 the eye. As indicated above, the trabecular meshwork has been proposed to play an important role in the normal outflow of the aqueous fluid, and has been presumed to be the major site of outflow resistance in glaucomatous eyes.
An increased resistance to outflow through the trabecular 10 meshwork is believed to cause the elevated IOP observed in POAG
and other major glaucoma syndromes. The present invention pertains to a recognition that the health and viability of the cells which provide the endothelial lining of the trabecular meshwork structure are essential in preserving the integrity of the outflow 15 channels. A loss in the number and/or function of these cells results in the development of pathological changes which lead to the collapse or covering of the structures of the outflow pathway, or otherwise compromise the normal function of such structure.
The result of such changes is the increased outflow resistance 20 observed in POAG and other forms of glaucoma (e.g., pigmentary glaucoma).
The present invention is thus directed to methods for treating trabecular meshwork cells subject to cell loss in order to maintain the number of the trabecular cells. Treatments that 25 protect the viability of cells of the trabecular meshwork from agents or processes that would otherwise cause trabeular cell loss are referred to herein as "cyto-protective" treatments.
As used herein, a treatment is said to have "minor to null"
effect if it results in an increase in cytoprotection relative to 30 untreated controls of less than 10%. A treatment is said to have "minimal" effect if it results in an increase in cytoprotection relative to untreated controls of 10-20%. A treatment is said to have "substantial" effect if it results in an increase in cytoprotection relative to untreated controls of between 20-50%.
35 A treatment is said to have "major" effect if it results in an W o 96/40102 PCTAUS96/07340 increase in cytoprotection relative to untreated controls of between greater than 50%.
I l . The Cyto-Protection of Trabecular Cells The cyto-protective treatments of the present invention may be used to protect trabecular cells against loss caused by a diverse set of harmful agents or processes. Examples of such agents and processes include agents that cause oxidative injury, and cell-mediated processes (such as phagocytosis and endocytosis of toxic materials) that have a negative effect on 1 0 trabecular meshwork cells.
A. Agents and Proce-~ses Causing Tr~hec~ r Cell Loss 1. Oxidative Injury Human trabecular meshwork cells encounter relatively high concentrations of hydrogen peroxide and other reactive oxygen species. The stress from these factors has been proposed to result in decreased human trabecular meshwork function, involving loss of trabecular meshwork cells and loss of normal outflow architecture, thereby impeding the outflow of aqueous humor (Polansky, J.R. et a/., In: Principles and Practice of Ophthalmology, pp. 226-247, W.B. Saunders & Company, Philadelphia (1994)). Experiments to test this proposal at first only demonstrated injury if relatively high levels (i.e., >1 mM) of hydrogen peroxide were employed, and if defensive enzymes were inhibited (Bhuyan, K.C. et al., Biochem. Biophys. Acta 497:641 (1977); Bhuyan, K.C. et a/., In: "Biochemical and Clinical Aspects of Oxygen," Caughey, W.S. (ed.) p. 795 (1981); Spector, A. et al., Exper.
Eye Res 33:673 (1981); Giblin, F.J. et al., Invest. Ophthalmol. Vis.
Sci. 22:330 (1982); Kahn, M.G. et al., Invest. Ophthalmol. Vis. Sci.
24:1283-1287 (1983)). However, it was later discovered that lower levels of hydrogen peroxide (i.e., 0.05-0.1 mM) can produce noticeable effects in trabecular meshwork cells if the hydrogen peroxide exposure were maintained for 1-2 hours rather than W O 96/40102 PCTrUS96/07340 using only a brief exposure (Polansky, J.R., et al., CLAO
suppl. 1 6:S23 (1990)).
One aspect of the present invention concerns the recognition that the reduced outflow ability of the meshwork that is observed 5 in glaucomatous patients is caused in part by toxic oxidative agents in the aqueous humor. Such agents induce an oxidative injury or oxidative stress to the trabecular meshwork. Since the meshwork is not in direct light, the main causes of the oxidative injury are stable oxidizing species, such as hydrogen peroxide or 10 lipidhydroperoxides, or their breakdown products (Polansky, J.R. e t al., In: Principles and Practice of Ophthalmology, page 226-247, W.B. Saunders & Company, Philadelphia (1994); Bhuyan, K.C. et al., Biochem. Biophys. Acta 497:641-651 (1977); Bhuyan, K.C. et al., In:
"Biochemical and Clinical Aspects of Oxygen," Caughey, W.S. (ed.) 1 5 p. 785-796 (1981); Spector, A. et al., Exper. Eye Fles 33:673-381 (1981); Giblin, F.J. et al., Invest. Ophthalmol. Vis. Sci. 22:330-335 (1982); Babizhayev, M.A. et al., Invest. Ophthalmol. Vis. Sci. 67:371 (1989)).
In this regard, substantial levels of hydrogen peroxide 20 (approximately 0.03 mM) are present in normal aqueous fluid and alterations of normal physiology can significantly increase these levels (Giblin, F.J. et al., Invest. Ophthalmol. Vis. Sci. 22:330-335 (1982); Kahn, M.G. et al., Invest. Ophthalmol. Vis. Sci. 24:1283-1287 (1983)). It has been proposed that normal animals detoxify 25 hydrogen peroxide via coupled reactions involving glutathione peroxidase, glutathione reductase and the hexose monophosphate shunt (Giblin, F..l. et al., Invest. Ophthalmol. Vis. Sci. 22:330-335 (1982)). Catalase is also believed to contol hydrogen peroxide concentration. Processes that impair the capacity of the 30 trabecular meshwork to control peroxide concentration increases the likelihood of oxidative injury (Kahn, M.G. et al., Invest.
Ophthalmol. Vis. Sci. 24:1283-1287 (1983); Nguyen, K.P.V. et al., Invest. Ophthamol. Vis. Sci. 29:976-981 (1988)). The trabecular meshwork plays a substantial role in removing excess hydrogen 35 peroxide from the aqueous (Nguyen, K.P.V. et al., Invest. Ophthamol.
Vis. Sci. 29:976-981 (1988)).

W O 96/40102 PCT~US96/07340 2 . Cell-Mediated Injury Human trabecular meshwork cells are capable of actively attacking debris blocking the outflow channels by both phagocytosis and endocytosis (Polansky, J.R. et al., In: Principles and Practice of Ophthalmology, page 226-247, W.B. Saunders &
Company, Philadelphia (1994)). As used herein, phagocytosis is the capture and readsorption of cells or major fragments of cellular debris. In contrast, endocytosis is the capture and readsorption of minor fragments of cellular debris, macromolecuiar complexes, pigment, etc. The phagocytic/
endocytic abilities of human trabecular meshwork cells permit them to act as a "self-cleaning filter" (Rohen, J.W. et al., Graefes Arch. Clin. Exper. Ophthamol. 175:143 (1968); Ringvold, A. et al., Virchows Arch. [Pathol. Anat.] 353:110 (1971); Shabo, A.L. et al., Amer. J. Ophthamol. 73:25 (1972)).
Although such processes naturally occur, it is believed that phagocytosis of toxic materials released into the anterior chamber cause cell damage and loss. In the course of certain secondary glaucomas (i.e., glaucoma associated with pigment 20 dispersion), the cells of the trabecular meshwork are subjected to excessive phagocytic and/or endocytic attack of materials that become toxic, leading to cell damage and loss. The endocytosis of pigment associated with cell membrane fragments is believed to have a toxic effect on human trabecular meshwork cells, and this 25 effect appears greater if the membranes have been oxidized in preliminary studies (Polansky, J.R. et al., In: Principles and Practice of Ophthalmology, page 226-Z47, W.B. Saunders &
Company, Philadelphia (1994)).

B. Cyto-prote~ e Agents A second aspect of the present invention concerns the recognition that non-steroidal anti-inflammatory ("NSAI") agents are able to counter the effect of such injury, whether due to oxidation or other causes, and to thereby prevent or treat (i.e.

W O 96/40102 PCTrUS96/07340 slow or minimize) the loss of trabecular meshwork cells. Such agents are able to disrupt the pathogenic processes that cause the reduced outflow facility and elevated IOP of glaucomas. Such agents therefore may be used to treat chronic glaucomas or 5 pigmentary glaucoma that are induced or aggravated by the loss of trabecular meshwork cells.
NSAI agents have been previously used in the eye primarily to treat inflammatory conditions and pain (see, for example, U.S.
Patents Nos. 4,960,799; 4,829,088, 5,11 0,493). This includes 10 their application as topical agents in the eye, in which their ability to suppress inflammatory responses and to prevent particular side-effects of surgical trauma (on the pupil preventing surgical meiosis), fluid accumulating in the back of the eye after cataract surgery (post-surgical macular edema) and the 15 appearance of inflammatory cells and vessel leakage in the anterior chamber. Topical application of NSAI agents in the eye also appear to relieve some of the itching due to allergic conjunctivitis. These conditions fit in the normal and expected effects of NSAI agents in inflammation and pain. In view of the 20 known mechanisms of action of NSAI agents to lower prostaglandin (and other eicosanoid) production, it is quite surprising that such agents could provide a cyto-protective effect on trabecular meshwork cells, and prevent cell loss. It is especially surprising that a pretreatment of the cells with these 25 agents would prevent subsequent injury even if the drug is not present in the fluid surrounding the cells at the time of injury.
The concept that NSAI agents could be used in the treatment of "inflammatory glaucoma" (i.e., inflammation in the anterior part of the eye (anterior uveitis)) has been previously proposed. In 30 this glaucoma syndrome, it is thought that inflammatory cells from acute inflammation contribute to an elevated IOP which can become very dangerous if not treated. It was proposed, but never proven, that this glaucoma syndrome might be treated by decreasing inflammation with NSAI agents. Because NSAI agents 35 have not been found to have a major effect in treating inflammatory glaucoma, they are not generally used for this w o 96/4010Z PCTrUS96/07340 condition. Instead, corticosteroids are the drugs of choice to treat inflammation in patients with inflammatory glaucoma; these drugs are used along with palliative measures that help to keep the IOP down, until inflammatory processes are brought under 5 control.
I l l . The Preferred Agents of the Invention The preferred agents of the present invention comprise non-steroidal anti-inflammatory agents that are able to prevent or lessen a damage to, or a loss of, trabecular cells, that is caused 10 by a variety of mechanisms including oxidative injury to the tissues of the eye, and especially to the trabecular meshwork.
One class of NSAI agents that may be used in accordance with the methods of the present invention are "eicosanoid inhibiting agents." Eicosanoid inhibiting agents include those 15 compounds which inhibit prostaglandin and other eicosanoid or cyclooxygenase pathways which are believed to affect IOP.
Compounds considered within the classification of eicosanoid inhibitors include certain NSAI agents. The ability of a drug to suppress cyclooxygenase activity and eicosanoid synthesis in 20 model systems does not appear to predict the cyto-protective effects observed.
NSAI agents have been documented by J. Lombardino in Nonsteroidal Anti-inflammatory Drugs, Wiley-lnterscience, New York, (1985). Examples of compounds of this class of anti-25 inflammatory drugs include but are not limited to the following:aspirin, benoxaprofen, benzofenac, bucloxic acid, butibufen, carprofen, cicloprofen, cinmetacin, clidanac, clopirac, diclofenac, etodolac, fenbufen, fenclofenac, fenclorac, fenoprofen, fentiazac, flunoxaprofen, furaprofen, flurbiprofen, furobufen, furofenac, 30 ibuprofen, ibufenac, indomethacin, indoprofen, isoxepac, ketoprofen, lactorolac, lonazolac, metiazinic, miroprofen, naproxen, oxaprozin, oxepinac, phenacitin, pirprofen, pirazolac, protizinic acid, sulindac, suprofen, tiaprofenic acid, tolmetin, and zomepirac.

W O 96/40102 PCT~US96/07340 Non-steroidal eicosanoid inhibiting compounds can be prepared in the form of pharmaceutically acceptable salts, esters and other prodrugs. Derivative salts include relatively non-toxic inorganic or organic acid addition salts or alkaline earth metal 5 salts of the therapeutic compounds, which can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the free base with a suitable organic or inorganic acid. Where the compounds include a basic functionality such as amine or alkylamine, representative salts include 10 hydrochloride, sulfate, acetate, maleate, lauryl sulphate, and the like. Where an acidic functionality is present, salts such as sodium, calcium, potassium and magnesium salts may be formed.
Additional examples of NSAI agents include non-narcotic analgesiclnon-steroidal anti-inflammatory compounds such as (1 ) 15 propionic acid derivatives, (2) acetic acid derivatives, (3) fenamic acid derivatives, (4) biphenylcarboxylic acid derivatives and (5) oxicams.
While some of these agents are primarily used at the present time as anti-inflammatory agents and others are primarily used 20 as analgesics, in fact all of the contemplated compounds have both analgesic and anti-inflammatory activity and can be used at appropriate dosage levels for either purpose in various compositions.
The compounds in groups (1 ) through (4) typically contain a 25 carboxylic acid function; however, those acids are sometimes administered in the form of their pharmaceutically acceptable acid addition or alkali metal salts, e.g., sodium salts.
The propionic acid derivatives include, but are not limited to, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, 30 fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alimoprofen, tiaprofenic acid, fluprofen and bucloxic acid. Structurally related propionic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed 35 by this group.

CA 02222929 l997-l2-Ol W O 96~4~2 ' PCTrUS96rO7340 Thus, "propionic acid derivatives" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs - having a free--CH(CH3)COOH or --CH2CH2COOH group (which optionally can be in the form of a pharmaceutically acceptable 5 salt group, e.g.,--CH(CH3)COO--Na~), typically attached directly or via a carbonyl function to a ring system, preferably to an aromatic ring system.
Acetic acid derivatives as defined herein include, but are not limited to, indomethacin, sulindac, tolmetin, zomepirac, 10 diclofenac, fenclofenac, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac and oxpinac. Structurally related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
Thus, "acetic acid derivatives" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs having a free--CH2COOH group (which optionally can be in the form of a pharmaceutically acceptable salt group, e.g., --CH2COO- Na'), typically attached directly to a ring system, preferably to an 20 aromatic or heteroaromatic ring system.
Fenamic acid derivatives as defined herein include, but are not limited to, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid. Structurally related fenamic acid derivatives having similar analgesic and 25 anti-inflammatory properties are also intended to be encompassed by this group.
Thus, "fenamic acid derivative" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure <~NH~

COOH

W O 96/40102 PCTrUS96/07340 which can bear a variety of substituents and in which the free -COOH group can be in the form of a pharmaceutically acceptable salt group, e.g.,--COO~ NA+ .
The biphenylcarboxylic acid derivatives as defined herein 5 include, but are not limited to, diflunisal and flufenisal.
Structurally related biphenylcarboxylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
Thus, "biphenylcarboxylic acid derivative" as defined herein 10 are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure COOH
15 which can bear a variety of substituents and in which the free -COOH group can be in the form of a pharmaceutically acceptable salt group, e.g.,--COO~ NA+.
The oxicams as defined herein include, but are not limited to, piroxicam, sudoxicam, isoxicam, and CP-14,304. Structurally 20 related oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. A
preferred member of this group is piroxicam.
Thus, "oxicams" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which have the 25 general formula:

~GNH-R
s~N ~

~2 W O 96/40102 PCTrUS96/07340 wherein R is an aryl or heteroaryl ring system.
Also included within the non-steroidal eicosanoid inhibitors - or NSAI agents of the present invention are certain cyclooxygenase inhibitors as described by Flach, A.J., Survey Ophthalmology 36:259-284 (1992). Cyclo-oxygenase inhibitors are non-steroidal antiinflammatory drugs that have become available as ophthalmic eyedrops for treatment of inflammation.
These inhibitors may be grouped into six different classes:
salicylates, fenamates, indoles, phenylalkanoic acids and pyrazolones. Specific drugs within the respective groups are summarized below.

Cyclo-oxygenase Inhibitors Chemical Class Generic Name Salicylates Aspirin, Salicylic Acid,Diflunisol Indoles Indomethacin, Sulinda, Tolmetin Phenylalkanoic acids Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Ketorolac, Naproxen, Piroxicam, Suprofen Phenylacetic acids Diclofenac Pyrazolons Oxyphenbutazone, Phenylbutazone, Antipyrine, Aminopyrine, Azapropazone I V . Methods of Administration The agents of the present invention can be formulated according to known methods to prepare pharmaceutically acceptable compositions, whereby these materials, or their functional derivatives, having the desired degree of purity are combined in admixture with a physiologically acceptable carrier, excipient, or stabilizer. Such materials are non-toxic to recipients at the dosages and concentrations employed.
A composition is said to be "pharmaceuticaliy acceptable" if its administration can be tolerated by a recipient patient. An 5 agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
Preferably, such compositions are administered topically in an aqueous polymeric solution, aqueous suspension, ointment or gel vehicle.
Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington's Pharmaceutical Sciences (1 6th ed., Osol, A., Ed., Mack, Easton PA (1980)).
If the composition is to be water soluble, it may be formulated in a buffer such as phosphate or other organic acid salt preferably at a pH of about 7 to 8. If the composition is only partially soluble in water, it may be prepared as a microemulsion by formulating it with a nonionic surfactant such as Tween, Pluronics, or PEG, e.g., Tween 80, in an amount of, for example, 0.04-0.05% (w/v), to increase its solubility. The term "water soluble" as applied to the polysaccharides and polyethylene glycols is meant to include colloidal solutions and dispersions. In general, the solubility of the cellulose derivatives is determined by the degree of substitution of ether groups, and the stabilizing derivatives useful herein should have a sufficient quantity of such ether groups per anhydroglucose unit in the cellulose chain to render the derivatives water soluble. A degree of ether substitution of at least 0.35 ether groups per anhydroglucose unit is generally sufficient. Additionally, the cellulose derivatives may be in the form of alkali metal salts, for example, the Li, Na, K
or Cs salts.
Optionally other ingredients may be added such as antioxidants, e.g., ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides;
proteins, such as serum albumin, gelatin, or immunoglobulins;
hydrophilic polymers such as polyvinyl pyrrolidone; amino acids, W ~ g6140102 PCTAUS96/07340 such as glycine, glutamic acid, aspirin, or arginine;
monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; and sugar alcohols such as mannitol or sorbitol.
Additional pharmaceutical methods may be employed to control the duration of action. Controlled or sustained release preparations may be achieved through the use of polymers to complex or absorb the molecule(s) of the composition. The controlled delivery may be exercised by selecting appropriate macromolecules (for example, polyesters, polyamino acids, polyvinyl pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release.
Sustained release formulations may also be prepared, and include the formation of microcapsular particles and implantable articles. For preparing sustained-release compositions, the molecule(s) of the composition is preferably incorporated into a biodegradable matrix or microcapsule. A suitable material for this purpose is a polylactide, although other polymers of poly-(a-hydroxycarboxylic acids), such as poly-D-(-)-3-hydroxybutyric acid (EP 133,988A), can be used. Other biodegradable polymers include poly(lactones), poly(orthoesters), polyamino acids, hydro-gels, or poly(orthocarbonates) poly(acetals). The polymeric material may also comprise polyesters, poly(lactic acid) or ethylene vinylacetate copolymers. For examples of sustained release compositions, see U.S. Patent No. 3,773,919, EP 58,481A, U.S. Patent No. 3,887,699, EP 158,277A, Canadian Patent No.
1176565, Sidman, U. et al., Biopolymers 22:547 (1983), and Langer, R. et al., Chem. Tech. 12 98 (1982).
Alternatively, instead of incorporating the molecule(s) of the composition into polymeric particles, it is possible to entrap these materials in microcapsules prepared for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatine-microcapsules and CA 02222929 l997-l2-Ol poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).
In an alternative embodiment, liposome formulations and methods that permit intracellular uptake of the molecule will be employed. Suitable methods are known in the art, see, for example, Chicz, R.M. et a/. (PCT Application WO 94/04557), Jaysena, S.D. et al. (PCT Application WO93/1223~), Yarosh, D.B.
(U.S. Patent No. 5,190,762), Callahan, M.V. et al. (U.S. Patent No.
5,270,052) and Gonzalezro, R.J. (PCT Application 91/05771), all herein incorporated by reference.
The pharmaceutical compositions of the present invention may be sterilized, as by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). The compositions may be stored in Iyophilized form or as a liquid solution. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of salts of the 20 molecules.
The compositions of the present invention can be applied topically as to the skin, or to the cornea. When applied topically, the molecule(s) of the composition may be suitably combined with other ingredients, such as carriers and/or adjuvants. There are no limitations on the nature of such other ingredients, except that they must be pharmaceutically acceptable and efficacious for their intended administration, and cannot degrade the activity of the active ingredients of the composition. Examples of suitable vehicles include ointments, creams, gels, or suspensions, with or 30 without purified collagen. The compositions also may be impregnated into transdermal patches, and bandages, preferably in liquid or semi-liquid form.
For obtaining a gel formulation, the molecule(s) of the composition formulated in a liquid composition may be mixed with 35 an effective amount of a water-soluble polysaccharide or synthetic polymer such as polyethylene glycol to form a gel of the W O 96/40102 PCT/U~,G~ 40 proper viscosity to be appiied topically. The polysaccharide that may be used includes, for example, cellulose derivatives such as etherified cellulose derivatives, including alkyl celluloses, hydroxyalkyl celluloses, and alkylhydroxyalkyl celluloses, for example, methylcellulose, hydroxyethyi cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, and hydroxypropyl cellulose; starch and fractionated starch; agar; alginic acid and alginates; gum arabic; pullullan; agarose; carrageenan; dextrans;
dextrins; fructans; inulin; mannans; xylans; arabinans; chitosans;
glycogens; glucans; and synthetic biopolymers; as well as gums such as xanthan gum; guar gum; locust bean gum; gum arabic;
tragacanth gum; and karaya gum; and derivatives and mixtures thereof. The preferred gelling agent herein is one that is inert to biological systems, non-toxic, simple to prepare, and not too runny or viscous, and will not destabilize the molecule(s) held within it. Preferably the polysaccharide is an etherified cellulose derivative, more preferably one that is well defined, purified, and listed in USP, e.g., methylcellulose and the hydroxyalkyl cellulose derivatives, such as hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxypropyl methylcellulose. Most preferred herein is methylcelll~'cse.
The polyethylene glycol useful for gelling is typically a mixture of low and high molecular weight polyethylene glycols to obtain the proper viscosity. For example, a mixture of a polyethylene glycol of molecular weight 400-600 with one of molecular weight 1500 would be effective for this purpose when mixed in the proper ratio to obtain a paste.
The compositions of the present invention can also be formulated for administration parenterally by injection, rapid infusion, nasopharyngeal absorption (intranasopharangeally), dermoabsorption, or orally. The compositions may alternatively be administered intramuscularly, or intravenously. Compositions for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such , W O 96/40102 PCTrUS96/07340 as ethyl oleate. Carriers, adjuncts or occlusive dressings can be used to increase tissue permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water.
Besides the inert diluents, such compositions can also include wetting agents, emulsifying and suspending agents, or sweetening, flavoring, coloring or perfuming agents. Alternative oral formulations include an aqueous solution, aqueous suspension, elixir, tablet, caplet or capsule.
If methylcellulose is employed in the gel, preferably it comprises about 2-5%, more preferably about 3%, of the gel and the molecule(s) of the composition is present in an amount of about 300-1000 ~lg per ml of gel. The dosage to be employed is dependent upon the factors described above. As a general proposition, the molecule(s) of the composition is formulated and delivered to the target site or tissue at a dosage capable of establishing in the tissue a maximum dose that is efficacious but not unduly toxic.
In the most preferred embodiment, the molecules of the invention will be provided to the cornea or surface of the eye, and permitted to absorb across the cornea into the anterior chamber of the eye. Methods that may be used for accomplishing such ocular drug delivery are described by Zun, L.S. (Emerg. Med. Clin.
North. Amer. 6:121 (1988)), Lee, V.H. (J. Ocular Pharmacol. ~.157 (1990)), Ellis, P.P. (In: Ocular Therapeutics and Pharmacology, 7th ed., Mosby, (1987)), Jannsen, H.J. (U.S. Patent 5,200,453), Chandrasekaran, S.K. et al. (PCT Appln. No. W089/06964) and (Vaughan, D. et al., In: General Ophthamology, Appleton & Lange, Norwalk, CT, pp. 213-230 (1992)).
Most preferably, however, such drug administration will be accomplished by combining effective amounts of the agents of the invention with any of the sustained release ophthalmic delivery W O 96/40102 ' PCT~US96/07340 systems described by Davis, J.P. et al. (U.S. Patent No. 5,192,535, herein incorporated by reference).
Such preferred sustained release topical ophthalmic medicament delivery systems comprise an aqueous suspension at a pH of from about 3 to about 6.5 and an osmotic pressure of from about 10 to about 400 mOsM containing from about 0.1% to about 6.5% by weight, based on the total weight of the suspension, of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and 10 less than about 5% by weight of a crosslinking agent, such weight percentages of monomers being based on the total weight of monomers polymerized. Desirably the polymer is prepared by suspension or emulsion polymerizing the monomer with the crosslinking agent to a particle size of not more than about 50 15 ~Lm, preferably not more than about 30 ~Lm, in equivalent spherical diameter. The suspension has an initial viscosity of from about 1,000 to about 30,000 centipoises (cp) and is administrable to the eye in drop form at that initial viscosity. The polymer has average particle size of not more than about 50 ~Lm, preferably not 20 more than about 30 llm, in equivalent spherical diameter. In general, such polymers will range in molecular weight estimated to be about 250,000 to about 4,000,000, and preferably about 500,000 to about 2,000,000.
Aqueous suspensions containing polymer particles prepared 25 by suspension or emulsion polymerization whose average dry particle size is appreciably larger than about 50 ~m in equivalent spherical diameter are less comfortable when administered to the eye than suspensions otherwise identical in composition containing polymer particles whose equivalent spherical 30 diameters are, on the average, below about 50 llm. Moreover, above the average 50 llm size, the advantage of substantially increased viscosity after administration is not realized.
The lightly crosslinked suspension is administrable in drop form, upon contact of the lower pH suspension with the higher pH
35 tear fluid of the eye, the suspension is rapidly gellable to a substantially greater viscosity than the viscosity of the suspension as originally administered in drop form. Accordingly, the resulting more viscous gel can remain in the eye for a prolonged period of time so as to release its NSAI agent over a prolonged time period.
A preferred drug delivery system employs a polymer that is preferably prepared from at least about 50% by weight, more preferably at least about 90% by weight, of one or more carboxyl-containing monoethylenically unsaturated monomers. Acrylic acid is the preferred carboxyl-containing, monoethylenically unsaturated monomer, but other unsaturated, polymerizable carboxyl-containin9 monomers, such as methacrylic acid, ethacrylic acid, ,B-methylacrylic acid (crotonic acid), cis-a-methylcrotonic acid (angelic acid), trans-a-methylcrotonic acid (tiglic acid), a-butylcrotonic acid, a-phenylacrylic acid, a-benzylacrylic acid, a-cyclohexylacrylic acid, ~-phenylacrylic acid (cinnamic acid), coumaric acid (o-hydroxycinnamic acid), p-hydroxycoumaric acid (umbellic acid), and the like can be used in addition to or instead of acrylic acid. Carbopol 976 and polycarbophil (Davis, et al., U.S. Patent 5, 192,535) are examples of suitable polymers.
Such polymers are crosslinked by using a small percentage, i.e., less than about 5%, such as from about 0.5% or from about 0.1% to about 5%, and preferably from about 0.2% to about 1%, based on the total weight of monomers present, of a polyfunctional crosslinking agent. The crosslinking agents of such compositions include non-polyalkenyl polyether difunctional crosslinking monomers such as divinyl glycol; 2,3-dihydroxyhexa-1,5-diene; 2,5-dimethyl-1,5-hexadiene; divinylbenzene; N,N-diallylacrylamide; N,N-diallylmethacrylamide and the like. A
preferred crosslinking agent is divinyl glycol. Also included are polyalkenyl polyether crosslinking agents containing two or more alkenyl ether groupings per molecule, preferably alkenyl ether groupings containing terminal H2C =C < groups, prepared by etherifying a polyhydric alcohol containing at least four carbon 3 5 atoms and at least three hydroxyl groups with an alkenyl halide such as allyl bromide or the like, e.g., polyallyl sucrose, polyallyl W O 96/4~102 PCT~US96/07340 pentaerythritol, or the like; see, e.g., Brown, U.S. Patent No.
2,798,053. Diolefinic non-hydrophilic macromeric crosslinking agents having molecular weights of from about 400 to about 8,000, such as insoluble di- and polyacrylates and methacrylates 5 of diols and polyols, diisocyanate-hydroxyalkyl acrylate or methacrylate reaction products, and reaction products of isocyanate terminated prepolymers derived from polyester diols, polyether diols or polysiloxane diols with hydroxyalkyl-methacrylates, and the like, can also be used as the crosslinking agents; see, e.g., Mueller et al., U.S. Patents Nos. 4,192,827 and 4, 1 36,250.
In a preferred method of preparing sustained release topical ophthalmic delivery systems, the foregoing suspensions are prepared and packaged at the desired viscosity of from 1,000 to about 30,000 centipoises, for administration to the eye in drop form. In a preferred delivery method, the foregoing suspensions, containing the medicament, are administered to the eye at the initial viscosity in drop form to cause the administered suspension, upon contact with the higher pH tear fluid of the eye, to rapidly gel in situ to a substantially greater viscosity than the viscosity of the suspension as originally administered in drop form. The more viscous gel remains in the eye for a prolonged period of time so as to release the medicament, entrapped in the more viscous gel formed in the eye, in sustained fashion.
It may be desirable to replace up to about 40% by weight of the carboxyl-containing monoethylenically unsaturated monomers by one or more non-carboxyl-containing monoethylenically unsaturated monomers containing only physiologically and ophthamologically innocuous substituents.
The desired osmotic pressure is preferably achieved by using a physiologically and ophthalmologically acceptable salt in an amount of from about 0.01% to about 1% by weight, based on the total weight of the suspensions. A preferred salt is sodium chloride .
Generally, the dosage needed to provide an effective amount of the composition will vary depending upon such factors as the recipient's age, condition, sex, and extent of disease, if any, and other variables, and can be adjusted and determined by one of ordinary skill in the art. Effective amounts of the compositions of the invention can vary from 0.01-1,000 mg/ml per dose or 5 application, although lesser or greater amounts can be used. For ophthalmic suspensions, the effective amounts will preferably be from about 0.0001% to about 10% by weight, and most preferably from about 0.01% to about 5% by weight, based on the total weight of the suspension.
For example, to provide cyto-protection for the trabecular meshwork of a human, and prevent the loss of trabecular cells, the composition of an ophthalmologically effective amount of a non-steroidal cyclooxygenase inhibitor, and a pharmaceutically acceptable carrier contains between about 0.001% and about 10%
15 by weight amount of the non-steroidal cyclooxygenase inhibitor.
The same compositions can be used to provide cyto-protection of the trabecular meshwork in humans in need of treatment or prevention of oxidative injury to its trabecular cells, or of damage to trabecular cells from phagocytic or endocytic processes. Most 20 preferably, for either use, the composition is administered to provide a concentration of inhibitor of less than about 1 x 10-5 M (and preferably between about 1 x 10-9 M and about 1 x 10-5 M) in the aqueous humor of the eye.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

Oxidative Stress To Human Trabecular Meshwork Cells Confluent monolayers of human trabecular meshwork cells were prepared using conventional methods (Polansky, J.R. et al., Invest. Ophthamol. Vis. Sci. 18:1043 (1979); Alvarado, J.A. et al., Invest. Ophthamol. Vis. Sci. 23:464 (1982); Polansky, J.R. et al., W O 96/40102 PCT~US96/07340 Proc. Int. Soc. Eye Res. 3:76 (1980); Polansky, J.R. et al., Vision Res. 21:155 (1981 ); Polansky, J.R. et a/., In: Principles and Practice of Ophthalmology, page 226-247, W.B. Saunders &
Company, Philadelphia (1994). Monolayers were exposed to 5 varying concentrations of hydrogen peroxide and other oxidants for their effects on human trabecular meshwork cell morphology and growth following trypsinization.
Morphological changes included an increase in detached cells and the appearance of dark granules in the cytoplasm if hydrogen 10 peroxide levels were maintained at approximately 0.3-1 mM for 1-2 hours. A shorter exposure or a decreased concentration was required to inhibit the growth of trabecular meshwork cells.
When non-steroidal anti-inflammatory agents are provided to cells subjected to oxidative injury, they were found to produce 15 cyto-protective effects in preventing these changes. The protective effects appear to be relatively cell-type specific based upon comparisons between human trabecular meshwork cells, ciliary epithelium, and retinal pigment epithelial cells.

Peroxide Effect on Protein Secretion by Cultured Trabecular Meshwork Cells The effect of hydrogen peroxide concentration on the capacity of cultured trabecular meshwork cells to secrete protein was investigated.
Human trabecular meshwork cells were cultured as described in Example 1.
The cells were then provided with aspirin, vitamin E, basic fibroblast growth factor (bFGF), ibuprofin, or tylenol (all at10-5 M) over a three day period; the media was then changed and the cells exposed to 0.3 mM hydrogen peroxide for 1 hour. After a 24 hour recovery period the amount of secreted protein was measured by assaying the extracellular radioactivity following a 2 hour 35S-methionine incorporation. The results of this experiment demonstrated that hydrogen peroxide had a profound inhibitory W O 96140102 PCTrUS96/07340 effect on the capacity of human trabecular meshwork cells to secrete protein. This inhibitory effect could be prevented by the presence of aspirin, Vitamin E, ibuprofin or tylenol, but not by bF~F.

Effect of NSAI Agents on Uptake of Rb by Cultured Trabecular Meshwork Cells Subjected to Oxidative Stress The effect of NSAI agents on the capacity of cultured trabecular meshwork cells exposed to oxidative injury to incorporate Rb was investigated.
Human trabecular cells were treated on both three and one days prior to oxidative stress with aspirin, diclofenac, Vitamin E
15 acetate, fenoprofen, flurbiprofen, ibuprofen, indomethacin, phenacetin, tolmetin, and acetaminophen. Solutions were prepared as 50 mM solutions in ethanol, diluted further in culture media and added as 1 00X dilutions. Oxidative stress was done by first rinsing the cells with 37 ~C phosphate buffered saline (PBS) and 20 then adding PBS or 0.6 mM H2O2 diluted with PBS. The cells were then placed in a 37 ~C water-jacketed incubator. After 1 hour, the cells were then changed back to their normal culture media. The following day, the culture media was removed and replaced with 86 RbCI (1 ~lCi/ml) diluted in PBS with 1 g/l glucose. After 25 incubation at 37 ~C for 20 minutes, the rubidium (Rb) solution was removed, the cells rinsed twice with ice cold PBS and the cells were then Iysed with 0.1 M NaOH. The Iysed cells were then counted using a scintillation counter. Table 1 gives the amount of rubidium incorporation for 1 ~lM and 10 !lM drug treatments;
30 control had no drug. Table 1 provides the 86Rb uptake of treated cells relative to that of the control, expressed as a percentage of the control. As shown, human trabecular meshwork cells pre-treated with diclofenac, fenoprofen, flurbiprofen, indomethacin and tolmetin had essentially normal ability to incorporate 3 5 rubidium.

W O 96/40102 PCTrUS96~07340 T ble 1 Drug Pre- Conc. % Relative 86Rb Uptake (cpm) Treatment (~M) ~ mM H2O20.6 mM H2O2 Con-rol 0 100 10 Asp r n 1 13 A~p r n 10 clofenac 1 ~3 clofenac 10 80 \/ tamin E Acetate 1 20 V tamin ' Acetate 10 20 Fenopro en 1 78 F~nopro en 10 75 F ur~ profen 1 83 F ur~ profen 10 8 bupro en 1 -~
b~pro en 10 ~-nc omethacin 1 c ometh cin 10 8-~ lenacet n PlF!nacet n 10 --o met n 1 6~
--o met n 10 8-Acetam nophen Acetam nophen 10 Effect of Different Concentrations of NSAI Agents on Uptake of Rb by Cultured Trabecular Meshwork Cells Subjected to Oxidative Stress The effect of NSAI agents on the capacity of cultured trabecular meshwork cells to incorporate Rb was investigated.
Human trabecular cells were treated on both three and one days prior to oxidative stress with aspirin, diclofenac, Vitamin E
acetate, fenoprofen, flurbiprofen, ibuprofen, indomethacin and acetaminophen. Solutions were prepared as 50 mM solutions in ethanol, diluted further in culture media and added as 1 00X

W O 96/40102 PCT~US96/07340 dilutions. Oxidative stress was done by first rinsing the cells with 37 ~C PBS and then adding PBS or 0.6 mM H2~2 diluted with PBS. The cells were then placed in a 37 ~C water-jacketed incubator. After 1 hour, the cells were then changed back to their 5 normal culture media. The following day, the culture media was removed and replaced with 86RbCI (111Ci/ml) diluted in PBS with 1 g/l glucose. After incubation at 37 ~C for 20 minutes, the rubidium solution was removed, the cells rinsed twice with ice cold PBS and the cells then were Iysed with 0.1 M NaOH. The Iysed 10 cells were then counted in a scintillation counter. Ther results of the experiment are shown in Table 2. Table 2 shows the 86Rb uptake of treated cells expressed as a percentage of the uptake of control cells. As shown in Table 2, rubidium uptake for the 1 ~M
pretreatments of diclofenac and flurbiprofen were at essentially 15 the same levels. However, substantial differences were found for the pretreatments with 0.1 and 0.01 ,uM diclofenac and flurbiprofen.
It was a particularly unexpected discovery that diclofenac worked at a very low dose in the assays, suggesting that 20 substantially lower doses of topical (and perhaps even systemic) diclofenac, as well as other non-steroidal agents, may prevent the progression of elevated intra-ocular pressure due to loss of and/or injury to trabecular meshwork cells.

-able 2 % Relative 86Rb Uptake (cpm) Drug Conc.H2O2Concentration Pre-Treatment (~M) ~ mM 0.6 mM1.0 mM
Control 100 2 4 A-,pirin 1 8 7 ~co enac 0.01 8 69 ~coenac 01 9 76 ~ c o enac 9~ 88 Vtamin E Acetate 2 3 Fenoprofen 0.1 4 3 '~no~rof~n 1 1 5 3, ~ urbpro en 0.01 7 v - urb pro-en 0.1 r~ 1 ' urb profen 1 8-buprofen ndomethacin - 9 9 Acetaminophen - 22 2 While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended 5 to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features 10 hereinbefore set forth and as follows in the scope of the appended claims.

Claims (32)

WHAT IS CLAIMED IS:
1. A method for cyto-protection of the trabecular meshwork comprising administering to a human a composition including (a) an ophthalmologically effective amount of a non-steroidal cyclooxygenase inhibitor, and (b) a pharmaceutically acceptable carrier, to prevent the loss of trabecular cells.
2. The method according to claim 1, wherein said cyclooxygenase inhibitor is selected from the group consisting of salicylates, indoles, phenylalkanoic acids, phenylacetic acids and pyrazolons.
3. The method according to claim 1, wherein said non-steroidal cyclooxygenase inhibitor is selected from the group consisting of diclofenac, indomethacin and fenoprofen.
4. The method according to claim 1, wherein said composition is administered topically in an aqueous polymeric solution, aqueous suspension, ointment or gel vehicle.
5. The method according to claim 1, wherein said composition comprises between about 0.001% and about 10% by weight of said cyclooxygenase inhibitor.
6. The method according to claim 6, wherein said composition comprises between about 0.001% and about 0.009% by weight of said inhibitor.
7. The method according to claim 1, wherein said composition is administered to provide a concentration of said inhibitor of less than about 1 x 10-5 M in the aqueous humor of the eye.
8. The method according to claim 7, wherein said composition is administered to provide a concentration of said inhibitor of between about 1 x 10-9 M and about 1 x 10-5 M in the aqueous humor of the eye.
9. The method according to claim 1, wherein said composition is administered by a method selected from the group consisting of intraocular injection, oral administration and intravenous injection.
10. The method according to claim 10, wherein said composition is administered orally, and wherein the composition is an aqueous solution, aqueous suspension, elixir, tablet, caplet or capsule.
11. A method for cyto-protection of the trabecular meshwork, comprising administering to a human a composition including (a) an ophthamologically effective amount of diclofenac, and (b) a pharmaceutically acceptable carrier, including a lightly cross-linkedcarboxy-containing polymer, in the form of an aqueous polymeric solution, suspension, ointment or gel for topical administration, to prevent the loss of trabecular cells.
12. The method according to claim 11, wherein said diclofenac is present in said formulation in an amount from about 0.001% to about 10% by weight of the composition.
13. The method according to claim 12, wherein said diclofenac is present in said formulation in an amount from about 0.001% to about 0.009% by weight of the composition.
14. The method according to claim 13, wherein said composition is administered in an amount sufficient to provide an ophthalmically effective amount of said diclofenac not exceeding 1 x 10-5 M in the aqueous humor of the eye.
15. A method for cyto-protection of the trabecular meshwork, comprising administering to a human in need of treatment or prevention of oxidative injury to its trabecular cells, or of damage to said trabecular cells from phagocytic or endocytic processes, a composition including (a) an ophthalmically effective amount of a non-steroidal anti-inflammatory cyclooxygenase inhibitor and (b) a pharmaceutically inert carrier, to prevent the loss of trabecular cells.
16. The method according to claim 15, wherein said non-steroidal anti-inflammatory cyclooxygenase inhibitor is selected from the group consisting of salicylates, indoles, phenylalkanoic acids, phenylacetic acids and pyrazolons.
17. The method according to claim 15, wherein said non-steroidal anti-inflammatory cyclooxygenase inhibitor is selected from the group consisting of diclofenac, indomethacin and fenoprofen.
18. The method according to claim 15, wherein said non-steroidal anti-inflammatory cyclooxygenase inhibitor is diclofenac.
19. The method according to claim 15, wherein said composition is administered topically in an aqueous polymeric solution, aqueous suspension, ointment or gel vehicle.
20. The method according to claim 15, wherein said composition comprises between about 0.001 and about 10%
by weight of said eicosanoid inhibitor.
21. The method according to claim 20, wherein said composition comprises between about 0.001% and about 0.009% by weight of said inhibitor.
22. The method according to claim 21, wherein said composition is administered to provide a concentration of said inhibitor of less than about 1 x 10-5 M in the aqueous humor of the eye.
23. The method according to claim 22, wherein said composition is administered to provide a concentration of said inhibitor of between about 1 x 10-9 M and about 1 x 10-5 M in the aqueous humor of the eye.
24. The method according to claim 15, wherein said composition is administered by a method selected from the group consisting of intraocular injection, oral administration and intravenous injection.
25. The method according to claim 24, wherein said composition is administered orally, and wherein the composition is an aqueous solution, aqueous suspension, elixir, tablet, caplet or capsule.
26. A composition for cyto-protection of the trabecular meshwork, comprising (a) a non-steroidal cyclooxygenase inhibitor of a type and in an amount to prevent trabecular cell damage or loss, and (b) a pharmaceutically acceptable carrier therefor.
27. The composition according to claim 26, wherein said cyclooxygenase inhibitor is diclofenac, indomethecin or fenoprofen.
28. The composition according to claim 27, wherein said cyclooxygenase inhibitor is diclofenac.
29. The composition according to claim 28, wherein said diclofenac is present in an amount between 0.001 and about 0.009% by weight.
30. The method of claim 15, wherein said human is in need of treatment or prevention of oxidative injury to its trabecular cells.
31. The method of claim 30, wherein said oxidative injury is caused by hydrogen peroxide or lipidhydroperoxide.
32. The method of claim 15, wherein said human is in need of treatment or prevention of damage to its trabecular cells from phagocytic or endocytic processes.
CA002222929A 1995-06-07 1996-05-21 Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork Abandoned CA2222929A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/479,185 US5599535A (en) 1995-06-07 1995-06-07 Methods for the cyto-protection of the trabecular meshwork
US08/479,185 1995-06-07

Publications (1)

Publication Number Publication Date
CA2222929A1 true CA2222929A1 (en) 1996-12-19

Family

ID=23902997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222929A Abandoned CA2222929A1 (en) 1995-06-07 1996-05-21 Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork

Country Status (6)

Country Link
US (1) US5599535A (en)
EP (1) EP0831801A1 (en)
JP (1) JPH11506729A (en)
AU (1) AU706841B2 (en)
CA (1) CA2222929A1 (en)
WO (1) WO1996040102A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) * 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
DE10030345A1 (en) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions
JP4865958B2 (en) 2001-05-23 2012-02-01 株式会社トクホン Analgesic anti-inflammatory patch with local action
US20030119000A1 (en) * 2001-11-05 2003-06-26 Jon Polansky Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
AU2005237543B2 (en) * 2004-04-26 2011-02-10 Alcon, Inc. Statins for the treatment of ocular hypertension and glaucoma
BR112012022073A2 (en) 2010-03-03 2017-10-31 Boehringer Ingelheim Vetmedica Gmbh use of meloxicam for the long-term treatment of musculoskeletal disorders in cats.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3732865A (en) * 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) * 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS58152811A (en) * 1982-03-08 1983-09-10 Sumitomo Chem Co Ltd Indomethacin eye drop composition
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4777174A (en) * 1982-07-22 1988-10-11 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
CH655656B (en) * 1982-10-07 1986-05-15
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4670254A (en) * 1983-12-09 1987-06-02 Toko Yakuhin Industry Co., Ltd. Gel preparations for topical application of diclofenac sodium
US4543251A (en) * 1983-12-09 1985-09-24 Toko Yakuhin Industry Co., Ltd. Gel preparations for external application
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
IL74694A0 (en) * 1984-04-02 1985-06-30 Merck & Co Inc N-alkenyl-3-hydroxybenzo(b)thiophene-2-carboxamide derivatives,their preparation and pharmaceutical compositions containing them
DE3413608A1 (en) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt IMPLANTABLE PREPARATIONS OF REGULATORY PEPTIDES WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
DE3446873A1 (en) * 1984-12-21 1986-07-10 Merckle Gmbh LIQUID DICLOFENAC PREPARATIONS
CH664085A5 (en) * 1985-02-08 1988-02-15 Ciba Geigy Ag PHARMACEUTICAL PREPARATIONS WITH ANALGETIC EFFECTIVENESS AND THEIR PRODUCTION.
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
JPS62123119A (en) * 1985-11-22 1987-06-04 Green Cross Corp:The Miotic inhibitor in ophthalmic operation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
JPH0610141B2 (en) * 1986-02-14 1994-02-09 新技術事業団 AIDS viral disease treatment agent
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
DE3612537C1 (en) * 1986-04-14 1987-07-16 Dispersa Ag Medicines used to treat inflammation in the eye
US4904649A (en) * 1986-05-23 1990-02-27 New England Medical Center Hospitals, Inc. Method and solution for treating glaucoma
CH666621A5 (en) * 1986-06-27 1988-08-15 Ciba Geigy Ag TOPICALLY APPLICABLE PHARMACEUTICAL COMPOSITIONS WITH SYSTEMIC EFFECT.
GB8625325D0 (en) * 1986-10-22 1986-11-26 Glaxo Group Ltd Chemical compounds
IT1228242B (en) * 1986-11-13 1991-06-05 Ricerfarma Srl Milano DICLOFENAC SALT WITH HYDROXYETHYLPYRROLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
CA1328614C (en) * 1987-09-11 1994-04-19 Cherng-Chyi Roger Fu Preservative system for ophthalmics formulations
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
DE3822095A1 (en) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab NEW MEDICAMENT FORMULATION AND METHOD FOR THE PRODUCTION THEREOF
US5190762A (en) * 1988-07-06 1993-03-02 Applied Genetics, Inc. Method of administering proteins to living skin cells
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
GB8921072D0 (en) * 1989-09-18 1989-11-01 Iolab Corp Preservative for ophthalmic solutions
AU6521790A (en) * 1989-10-13 1991-05-16 Hans Schreier Lipophilic acylpyrazinamide prodrugs
IL95942A0 (en) * 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
AU7793791A (en) * 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition for use in treating pain
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
EP0466650A2 (en) * 1990-07-11 1992-01-15 Warner-Lambert Company Improvements in non-steroidal anti-inflammatory therapy
US5270052A (en) * 1991-04-19 1993-12-14 New England Medical Center Hospitals, Inc. Methods and compositions for treatment of infection by intracellular parasites
IT1252692B (en) * 1991-11-27 1995-06-23 Zambon Spa PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC USE CONTAINING A NON-STEROID ANTI-INFLAMMATORY AND A DECONGESTANT AS ACTIVE INGREDIENTS
WO1993012234A1 (en) * 1991-12-13 1993-06-24 Sri International Antiviral reagents based on rna-binding proteins
US5304561A (en) * 1992-07-24 1994-04-19 Faezeh Sarfarazi New concept in glaucoma treatment
JPH08502244A (en) * 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ Immunomodulatory peptide
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5676944A (en) * 1993-10-06 1997-10-14 The Regents Of The University Of California Ocular therapy with homologous macrophages
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors

Also Published As

Publication number Publication date
EP0831801A1 (en) 1998-04-01
JPH11506729A (en) 1999-06-15
AU5800896A (en) 1996-12-30
WO1996040102A1 (en) 1996-12-19
AU706841B2 (en) 1999-06-24
US5599535A (en) 1997-02-04

Similar Documents

Publication Publication Date Title
US5674888A (en) Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) Methods for the cyto-protection of the trabecular meshwork
AU695888B2 (en) Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure
Solomon et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery
RU2102069C1 (en) Pharmaceutical composition for glaucoma treatment
CA1225033A (en) Opthalmic anti-inflammatory agents
EP0743852B1 (en) Treatment of normotensive glaucoma with valsartan
JPH01104023A (en) Preserving system for ophthalmic medicine
US5814655A (en) Non-steroidal ophthalmic mixtures
AU695699B2 (en) Non-steroidal anti-inflammatory ophthalmic suspensions
US5212168A (en) Method of and solution for treating glaucoma
CA2490707A1 (en) Method of using ryanodine antagonists in treating neural injury
BRPI0615245A2 (en) ep2 receptor agonists for treatment of glaucoma
JPWO2005079792A1 (en) Preventive or therapeutic agent for severe diabetic retinopathy
AU2005262652A1 (en) Abnormal Cannabidiols for lowering intraocular pressure
WO1995018604A1 (en) Topical treatment of ocular photophobia
US20050282912A1 (en) Abnormal cannabidiols as neuroprotective agents for the eye
MXPA97009609A (en) Non-steroid anti-inflammatory drugs for the cito-protection of mesh trabecu
MXPA97009605A (en) Treatment of a trabecular reticle whose cells are subject to the inhibition of the cellular division with non-steroid anti-inflammatory drugs
Suharwardy et al. A comparative trial between diclofenac-gentamicin and betamethasone-neomycin drops in patients undergoing cataract extraction
Flach Nonsteroidal anti-inflammatory drugs in ophthalmology
Flach Topical nonsteroidal antiinflammatory drugs for ophthalmic use
CA2177578C (en) Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
EP0456988B1 (en) Use of naproxen as mydriatic agent
Scheinblum et al. Drug therapy before, during, and after cataract surgery

Legal Events

Date Code Title Description
FZDE Discontinued